Enhanced gastrointestinal absorption of lipophilic drugs

Enhancement in Drug Delivery

Volumn , Issue , 2006, Pages 111-131

  Dahan, Arik ^a   Hoffman, Amnon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85055044603     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (101)

1. Lipinski, C.A., et al. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3.
2. Amidon, G.L., et al. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413.
3. Read, N.W., et al. 1977. Unstirred layer and kinetics of electrogenic glucose absorption in the human jejunum in situ. Gut 18:865.
4. Westergaard, H., and J.M. Dietschy. 1974. Delineation of the dimensions and permeability characteristics of the two major diffusion barriers to passive mucosal uptake in the rabbit intestine. J Clin Invest 54:718.
5. Wacher, V.J., et al. 1998. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87:1322.
6. Gottesman, M.M., I. Pastan, and S.V. Ambudkar. 1996. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6:610.
7. Benet, L.Z., and C.L. Cummins. 2001. The drug efflux-metabolism alliance: Biochemical aspects. Adv Drug Deliv Rev 50:S3.
8. Kolars, J.C., et al. 1991. First-pass metabolism of cyclosporin by the gut. Lancet 338:1488.
9. Yun, C., R. Okerholm, and F. Guengerich. 1993. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 21:403.
10. Fitzsimmons, M.E., and J.M. Collins. 1997. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256.
11. Thummel, K.E., et al. 1996. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491.
12. Hebert, M.F. 1997. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 27:201.
13. Lennernas, H. 2003. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141.
14. Hunt, J.N., and M.T. Knox. 1968. Control of gastric emptying. Am J Dig Dis 13:372.
15. Rozman, K., L. Ballhorn, and T. Rozman. 1983. Mineral oil in the diet enhances fecal excretion of DDT in the rhesus monkey. Drug Chem Toxicol 6:311.
16. Palin, K.J., and C.G. Wilson. 1984. The effect of different oils on the absorption of probucol in the rat. J Pharm Pharmacol 36:641.
17. Porter, C.J.H., S.A. Charman, and W.N. Charman. 1996. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: Effect of lipid vehicle dispersion. J Pharm Sci 85:351.
18. Tarr, B.D., and S.H. Yalkowsky. 1989. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res 6:40.
19. Kaneniwa, N., and N. Watari. 1974. Dissolution of slightly soluble drugs. I. Influence of particle size on dissolution behavior. Chem Pharm Bull (Tokyo) 22:1699.
20. Scholz, A., et al. 2002. Influence of hydrodynamics and particle size on the absorption of felodipine in Labradors. Pharm Res 19:42.
21. Atkinson, R.M., et al. 1962. The effect of griseofulvin particle size on blood levels in man. Antibiot Chemother 12:232.
22. Hargrove, J.T., W.S. Maxson, and A.C. Wentz. 1989. Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol 161:948.
23. Tokumura, T., et al. 1987. Enhancement of the oral bioavailability of cinnarizine in oleic acid in beagle dogs. J Pharm Sci 76:286.
24. Chakrabarti, S., and F.M. Belpaire. 1978. Biovailability of phenytoin in lipid containing dosage forms in rats. J Pharm Pharmacol 30:330.
25. Abrams, L.S., et al. 1978. Comparative bioavailability of a lipophilic steroid. J Pharm Sci 67:1287.
26. Hauss, D.J., et al. 1998. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci 87:164.
27. Carrigan, P.J., and T.R. Bates. 1973. Biopharmaceutics of drugs administered in lipid-containing dosage forms. I. GI absorption of griseofulvin from an oil-in-water emulsion in the rat. J Pharm Sci 62:1476.
28. Bates, T.R., andJ.A. Sequeria. 1975. Bioavailability of micronized griseofulvinfromcorn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans. J Pharm Sci 64:793.
29. Charman, W., et al. 1993. Effect of food and a monoglyceride emulsion formulation on danazol bioavailability. J Clin Pharmacol 33:381.
30. Myers, R.A., and V.J. Stella. 1992. Systemic bioavailability of penclomedine (NSC-338720) from oil-in-water emulsions administered intraduodenally to rats. Int J Pharm 78:217.
31. Gershanik, T., and S. Benita. 2000. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm 50:179.
32. Julianto, T., K.H. Yuen, and A.M. Noor, 2000. Improved bioavailability of vitamin E with a selfemulsifying formulation. Int J Pharm 200:53.
33. Vonderscher, J., and A. Meinzer, 1994. Rationale for the development of Sandimmune Neoral. Transplant Proc 26:2925.
34. Fahr, A. 1993. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 24:472.
35. Ritschel, W.A., et al. 1990. Improvement of peroral absorption of cyclosporine A by microemulsions. Methods Find Exp Clin Pharmacol 12:127.
36. Drewe, J., et al. 1992. Enhancement of the oral absorption of cyclosporin in man. Br J Clin Pharmacol 34:60.
37. Levy, G., et al. 1994. Cyclosporine Neoral in liver transplant recipients. Transplant Proc 26:2949.
38. Trull, A.K., et al. 1995. Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. Br J Clin Pharmacol 39:627.
39. Mueller, E.A., et al. 1994. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 11:151.
40. Kovarik, J.M., et al. 1994. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 83:444.
41. Mueller, E.A., et al. 1994. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 11:301.
42. Erkko, P., et al. 1997. Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis. Br J Dermatol 136:82.
43. Freeman, D., et al. 1995. Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients. Ther Drug Monit 17:213.
44. Porter, C.J., and W.N. Charman. 2001. Lipid-based formulations for oral administration: Opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs. J Recept Signal Transduct Res 21:215.
45. Humberstone, A.J., and W.N. Charman. 1997. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 25:103.
46. Pouton, C.W. 2000. Lipid formulations for oral administration of drugs: Non-emulsifying, selfemulsifying and self-microemulsifying drug delivery systems. Eur J Pharm Sci 11:S93.
47. Amidon, G.L., G.D. Leesman, and R.L. Elliott. 1980. Improving intestinal absorption of waterinsoluble compounds: A membrane metabolism strategy. J Pharm Sci 69:1363.
48. Chan, O.H., et al. 1998. Evaluation of a targeted prodrug strategy to enhance oral absorption of poorly water-soluble compounds. Pharm Res 15:1012.
49. Amidon, G.L. 1981. Drug derivatization as a means of solubilization: Physicochemical and biochemical strategies. In Techniques of solubilization of drugs, ed. S.H. Yalkowsky, 183. New York: Marcel Dekker.
50. Vyas, D.M., et al. 1993. Synthesis and antitumor evaluation of water soluble taxol phosphates. Bioorg Med Chem Lett 3:1357.
51. Ueda, Y., et al. 1993. Novel water soluble phosphate prodrugs of taxol(R) possessing in vivo antitumor activity. Bioorg Med Chem Lett 3:1761.
52. Fleisher, D., R. Bong, and B.H. Stewart. 1996. Improved oral drug delivery: Solubility limitations overcome by the use of prodrugs. Adv Drug Deliv Rev 19:115.
53. Mamidi, R.N., et al. 2002. Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats. Biopharm Drug Dispos 23:273.
54. Varia, S.A., and V.J. Stella. 1984. Phenytoin prodrugs V: In vivo evaluation of some water-soluble phenytoin prodrugs in dogs. J Pharm Sci 73:1080.
55. Loo, J.C., et al. 1981. Pharmacokinetic evaluation of betamethasone and its water soluble phosphate ester in humans. Biopharm Drug Dispos 2:265.
56. Fleisher, D., et al. 1986. Oral absorption of 21-corticosteroid esters: A function of aqueous stability and intestinal enzyme activity and distribution. J Pharm Sci 75:934.
57. Vierling, P., and J. Greiner. 2003. Prodrugs of HIV protease inhibitors. Curr Pharm Des 9:1755.
58. Doyle, T.W., and D.M. Vyas. 1990. Second generation analogs of etoposide and mitomycin C. Cancer Treat Rev 17:127.
59. Sessa, C., et al. 1995. Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J Clin Oncol 13:200.
60. Beaumont, K., et al. 2003. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist. Curr Drug Metab 4:461.
61. Ettmayer, P., et al. 2004. Lessons learned from marketed and investigational prodrugs. J Med Chem 47:2393.
62. Hussain, M.M. 2000. A proposed model for the assembly of chylomicrons. Atherosclerosis 148:1.
63. Charman, W.N., and V.J. Stella. 1986. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm 34:175.
64. Stella, V.J., and N.L. Pochopin. 1992. Lipophilic prodrugs and the promotion of intestinal lymphatic drug transport. In Lymphatic transport of drugs, eds. W.N. Charman, and V.J. Stella, 181. Boca Raton: CRC Press.
65. Daggett, P.R., M.J. Wheeler, and J.D. Nabarro. 1978. Oral testosterone, a reappraisal. Horm Res 9:121.
66. Nieschlag, E., et al. 1975. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol (Copenh) 79:366.
67. Horst, H.J., et al. 1976. Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klin Wochenschr 54:875.
68. Tauber, U., et al. 1986. Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. Eur J Drug Metab Pharmacokinet 11:145.
69. Shackleford, D.M., et al. 2003. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J Pharmacol Exp Ther 306:925.
70. Noguchi, T., W.N. Charman, and V.J. Stella. 1985. The effect of drug lipophilicity and lipid vehicles on the lymphatic absorption of various testosterone esters. Int J Pharm 24:173.
71. Lambert, D.M. 2000. Rationale and applications of lipids as prodrug carriers, Eur J Pharm Sci 11:S15.
72. Garzon-Aburbeh, A., et al. 1983. 1,3-dipalmitoylglycerol ester of chlorambucil as a lymphotropic, orally administrable antineoplastic agent. J Med Chem 26:1200.
73. Garzon-Aburbeh, A., et al. 1986. A lymphotropic prodrug of L-dopa: Synthesis, pharmacological properties, and pharmacokinetic behavior of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl) propanoyl]propane-1,2,3-triol. J Med Chem 29:687.
74. Deverre, J.R., et al. 1989. In-vitro evaluation of filaricidal activity of GABA and 1,3-dipalmitoyl-2-(4-aminobutyryl)glycerol HCl: A diglyceride prodrug. J Pharm Pharmacol 41:191.
75. Jacob, J.N., G.W. Hesse, and V.E. Shashoua. 1990. Synthesis, brain uptake, and pharmacological properties of a glyceryl lipid containing GABA and the GABA-T inhibitor gamma-vinyl-GABA. J Med Chem 33:733.
76. Loiseau, P.M., et al. 1994. Study of lymphotropic targeting and macrofilaricidal activity of a melphalan prodrug on the Molinema dessetae model. J Chemother 6:230.
77. Sakai, A., et al. 1993. Deacylation-reacylation cycle: A possible absorption mechanism for the novel lymphotropic antitumor agent dipalmitoylphosphatidylfluorouridine in rats. J Pharm Sci 82:575.
78. Dahan, A., and A. Hoffman. 2005. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur J Pharm Sci 24:381.
79. Carey, M.C., D.M. Small, and C.M. Bliss. 1983. Lipid digestion and absorption. Annu Rev Physiol 45:651.
80. Westergaard, H., and J.M. Dietschy. 1976. The mechanism whereby bile acid micelles increase the rate of fatty acid and cholesterol uptake into the intestinal mucosal cell. J Clin Invest 58:97.
81. Caliph, S.M., W.N. Charman, and C.J.H. Porter. 2000. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci 89:1073.
82. Cheema, M., K.J. Palin, and S.S. Davis. 1987. Lipid vehicles for intestinal lymphatic drug absorption. J Pharm Pharmacol 39:55.
83. Bergstedt, S.E., et al. 1990. A comparison of absorption of glycerol tristearate and glycerol trioleate by rat small intestine. Am J Physiol Gastrointest Liver Physiol 259:G386.
84. Field, F., E. Albright, and S. Mathur. 1988. Regulation of triglyceride-rich lipoprotein secretion by fatty acids in Caco-2 cells. J Lipid Res 29:1427.
85. van Greevenbroek, M.M., D.W. Erkelens, and T.W. de Bruin. 2000. Caco-2 cells secrete two independent classes of lipoproteins with distinct density: Effect of the ratio of unsaturated to saturated fatty acid. Atherosclerosis 149:25.
86. van Greevenbroek, M.M., et al. 1996. Effects of saturated, mono-, and polyunsaturated fatty acids on the secretion of apo B containing lipoproteins by Caco-2 cells. Atherosclerosis 121:139.
87. Charman, W.N., and V.J. Stella. 1986. Effects of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT. Int J Pharm 33:165.
88. Porter, C.J.H., et al. 1996. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: Effect of lipid class and lipid vehicle dispersion. J Pharm Sci 85:357.
89. Khoo, S.M., et al. 2001. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J Pharm Sci 90:1599.
90. Ichihashi, T., et al. 1992. Effect of oily vehicles on absorption of mepitiostane by the lymphatic system in rats. J Pharm Pharmacol 44:560.
91. Kuksis, A. 1987. Absorption of fat soluble vitamins. In Fat absorption, ed. A. Kuksis, 65. Boca Raton: CRC Press.
92. Edwards, G.A., et al. 2001. Animal models for the study of intestinal lymphatic drug transport. Adv Drug Deliv Rev 50:45.
93. Gershkovich, P., and A. Hoffman. 2005. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: Linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci 26:394.
94. Nerurkar, M.M., P.S. Burton, and R.T. Borchardt. 1996. The use of surfactants to enhance the permeability of peptides through caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res 13:528.
95. Dintaman, J.M., and J.A. Silverman. 1999. Inhibition of P-glycoprotein by D-a-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 16:1550.
96. Malingre, M.M., J.H. Beijnen, and J.H.M. Schellens. 2001. Oral delivery of taxanes. Invest New Drugs 19:1552.
97. Yang, S., et al. 2004. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 21:261.
98. Bailey, D.G., et al. 1998. Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101.
99. Dahan, A., and H. Altman. 2004. Food-drug interaction: Grapefruit juice augments drug bioavailability-Mechanism, extent and relevance. Eur J Clin Nutr 58:1.
100. Lilja, J.J., K.T. Kivisto, and P.J. Neuvonen. 1998. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 64:477.
101. Kupferschmidt, H.H., et al. 1998. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 45:355.